●Aurora kinases dawn as cancer drug targets. Sausville, E. A. Nature Medicine (March 2004)

●Delivering on the promise: HPV vaccines and cervical cancer. Schiller, J. T. & Davies, P. Nature Reviews Microbiology April (2004)

●Molecular targets in pituitary tumours. Heaney, A. P. & Melmed, S. Nature Reviews Cancer April (2004)

●Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Drusano, G. L. Nature Reviews Microbiology April (2004)

●Technology feature – drug target identification.Nature 11 March (2004)

●Microtubules as a target for anticancer drugs. Jordan, M. A. & Wilson, L. Nature Reviews Cancer April (2004)

●Chemogenomics: an emerging strategy for rapid target and drug discovery. Bredel, M. & Jacoby, E. Nature Reviews Genetics April (2004)

●The evolution of thalidomide and its IMiD derivatives as anticancer agents. Bartlett, J. B., Dredge, K. & Dalgleish, A. G. Nature Reviews Cancer April (2004)

●MGMT: its role in cancer aetiology and cancer therapeutics. Gerson, S. L. Nature Reviews Cancer April (2004)

Modulation of the expression of MGMT – which encodes the DNA-repair protein AGT – can increase the susceptibility of tumour cells to chemotherapy and protect normal tissues.

●Cannabinoids and neuroinflammation. Walter, L. & Stella, N. British Journal of Pharmacology March (2004)

●Immunotherapeutic uses of CpG oligodeoxynucleotides. Klinman, D. M. Nature Reviews Immunology April (2004)

Evidence shows that CpG oligodeoxynucleotides are safe for use in humans as immunoprotective agents, vaccine adjuvants and anti-allergens.

●Reality and immortality – neural stem cells for therapies. Rothstein, J. D. & Snyder, E. Y. Nature Biotechnology March (2004)

●The population genetics and evolutionary epidemiology of RNA viruses. Moya, A., Holmes, E. C. & González-Candelas, F. Nature Reviews Microbiology April (2004)

Progress has been made in understanding RNA virus evolution. This knowledge might be used to predict the emergence of drug resistance.

●Biotechnology financing dilemmas and the role of special purpose entities. Schiff, L. & Murray, F. Nature Biotechnology March (2004)